DM
KRYS icon

Deerfield Management’s Krystal Biotech KRYS Stock Holding History

Deerfield Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,166
Closed -$758K – 271
2024
Q3 		$758K Buy
4,166
+2,561
+160% +$494K 0.01% 204
2024
Q2 		$295K Buy
+1,605
New +$269K ﹤0.01% 347
2023
Q2 		– Sell
-311,949
Closed -$25M – 106
2023
Q1 		$25M Buy
311,949
+136,949
+78% +$10.8M 0.56% 47
2022
Q4 		$13.9M Hold
175,000
– – 0.29% 66
2022
Q3 		$12.2M Buy
+175,000
New +$12.6M 0.24% 76

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deerfield Management's KRYS Position: Q4 2024 in Review

Deerfield Management sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 4,166 shares — an estimated $758K sold.

Deerfield Management first reported a position in KRYS in Q3 2022 and held it in 5 quarters. The position peaked at $25M in Q1 2023. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

  • Deerfield Management reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
  • Deerfield Management sold 4,166 Krystal Biotech shares in Q4 2024, an estimated $758K.
  • Deerfield Management first reported a position in Krystal Biotech in Q3 2022 and held it in 5 quarters.
  • Deerfield Management's Krystal Biotech position peaked at $25M in Q1 2023.
  • 264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.